<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643045</url>
  </required_header>
  <id_info>
    <org_study_id>NW 1015/015/III/2003</org_study_id>
    <nct_id>NCT00643045</nct_id>
  </id_info>
  <brief_title>Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist</brief_title>
  <official_title>A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newron Pharmaceuticals SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newron Pharmaceuticals SPA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of two dose ranges of safinamide (High Dose: 150 to 200
      mg/day and Low Dose: 50 to 100 mg/day) orally, as compared to Placebo, as add-on therapy in
      patients with early idiopathic Parkinson's disease who are currently receiving a stable dose
      of a single dopamine agonist. It is hypothesized that, over a 24-week period, add-on
      treatment with safinamide will result in greater improvement of motor symptoms in these
      patients, compared to treatment with a dopamine agonist alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UPDRS Section III (Motor Examination [ME]) total score at Baseline, each post-baseline visit and Endpoint (Visit 8 [Week 24]).</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS Section III (ME) item (&amp; total) scores.CGI Change from Baseline score.UPDRS Section II (ADL) item (&amp; total) scores.CGI Severity of Illness score. H&amp;Y Staging.All above at each visit and Endpoint (LOCF). Cogtest PD battery score each visit</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Idiopathic Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose (50-100mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose (150-200 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of idiopathic Parkinson's disease of less than 5 years
             duration, and a Hoehn and Yahr Stage of I to III,

          -  who were receiving treatment with a single dopamine agonist at a stable dose for at
             least 4 weeks prior to Visit 1 (Screening).

        Exclusion Criteria:

          -  Patients with medical conditions and/or taking concomitant medications that would have
             put them at risk, interfered with the study evaluations, or made them unable to
             complete the requirements of the study;

          -  patients with a diagnosis or recent history of substance abuse,

          -  a history of psychosis,

          -  who were depressed,

          -  had evidence of dementia or cognitive dysfunction,

          -  or who were experiencing end of dose wearing-off;

          -  female patients of childbearing potential;

          -  patients who have previously received safinamide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Merello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto FLENI, Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolando Giannaula, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Español - Servicio de Neurologia, Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federico Micheli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas, Servicio de Movimientos, Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelo Miranda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liga Chilena Contra el Mal De Parkinson, Santiago, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Saez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Barros Luco Trudeau, Servicio de Neurologia, Santiago, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roque Villagra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Salvador-Neurologia, Santiago, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Takeuchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundaciόn Valle de Lili Direcciόn Médica, Cali-Valle, Colombia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauricio Acevedo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Militar, Departamento de Neurología, Bogotà-D.C, Colombia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Lorenzana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultorio, Bogotà-D.C, Colombia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madhuri Behari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, All India Institute of Medical Science (AIIMS), New Delhi, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohit Bhatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Movement Disorder Clinic, Jaslok Hospital, Mumbai, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rupam Borgohain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nizam's Institute of Medical Sciences (NIMS), Hyderabad, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arunkumar Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>B.Y.L. Nair Hospital &amp; T.N. Medical College, Mumbai, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajit Roy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St John's Medical College &amp; Hospital, Bangalore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Babu Rao Muthane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health and Neuro Sciences, Bangalore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrizio Stocchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Neuromed Via Atinense 18 Pozzilli (IS), Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonardo Scarzelia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Evangelico Valdese, Torino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianpietro Nodera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Neurologia Casa di Cura &quot;Villa Margherita&quot;, Vicenza, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pezzoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isituti Clinici di Perfezionamento Centro Parkison, Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leontino Battistin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Neuroscienze, Padova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Onofri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divisione di Neurologia, Ospedale civile di Pescara, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Lamberti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Neurologica I Policinico di Bari, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandra Monge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osp. S. Giovanni Battista, Roma, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Barone, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Scienze Neurologiche, Universita di Napoli Federico II, Naples, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Abruzzese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Neuroscienze DINOG, Universita degli Studi di Genova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Marconi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale della Misericordia, Grosseto, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kulisevsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Serv. Neurologia, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lopez Lozano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Puerta de Hierro, Serv. Neurologia, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Vacquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Clinico San Carlos, Ser. Neurologia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Schapira, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Royal Free Hospital, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaudhuri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Day Hospital, Care of the Elderly, Lewisham University Hospital, London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Centre for Brain Repair, Cambridge, UK</affiliation>
  </overall_official>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>March 24, 2008</last_update_submitted>
  <last_update_submitted_qc>March 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Stefano Rossetti</name_title>
    <organization>Newron Pharmaceuticals S.p.A.</organization>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

